Announced details
Adenovirus infections after hematopoietic stem cell transplantation (UK)
45 registered patients in the global Phase III clinical trial as of the end of October 2026
The company will hold a pre-submission consultation in connection with the application for marketing authorization of BCV in the UK. シンバイオ製薬 obtained a global license for BCV in September 2019.
An agency under the UK's Department of Health and Social Care. It is the executive agency responsible for the authorisation and safety of medicines and medical devices.
No impact on the consolidated earnings outlook for the fiscal year ending December 2026
The company does not address Contract Value / Offering price.
IDWeek 2024 (Infectious Diseases Society of America conference) and the press release dated 23 October 2024
| Item | Details |
|---|---|
| Names of Products / Services Covered | Brincidofovir (BCV) / SyB V-1901 injection |
| Counterparty | Medicines and Healthcare products Regulatory Agency (MHRA) |
| Counterparty overview | An agency under the UK's Department of Health and Social Care. It is the executive agency responsible for the authorisation and safety of medicines and medical devices. |
| Relationship with the Company | The company will hold a pre-submission consultation in connection with the application for marketing authorization of BCV in the UK. シンバイオ製薬 obtained a global license for BCV in September 2019. |
| Launch date | 3 December 2026 (scheduled date of pre-submission consultation) / End of January 2027 (scheduled submission of formal application) |
| Applicable area | Adenovirus infections after hematopoietic stem cell transplantation (UK) |
| Usage history | 45 registered patients in the global Phase III clinical trial as of the end of October 2026 |
| Impact on Business Performance | No impact on the consolidated earnings outlook for the fiscal year ending December 2026 |
| Source | IDWeek 2024 (Infectious Diseases Society of America conference) and the press release dated 23 October 2024 |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In preparation for the marketing authorization application scheduled for January 2027, the company will incorporate advice and views from the MHRA into the application documents, enhance the application and improve the prospects of obtaining approval.